Jan 10 (Reuters) - Staidson Beijing BioPharmaceuticals Co Ltd
* Says it sees FY 2017 net profit could rise by up to 5 percent, or to be 257.3 million yuan to 270.1 million yuan
* Says the net profit of FY 2016 was 257.3 million yuan
* Comments that increased income of polyethylene glycol electrolyte as main reason for the forecast
Source text in Chinese: goo.gl/Rtxod1
Further company coverage: (Beijing Headline News)
Our Standards: The Thomson Reuters Trust Principles.